Ciclosporin Explained

Verifiedfields:changed
Watchedfields:changed
Verifiedrevid:459588806
Width:250
Width2:250
Usan:cyclosporine
Pronounce:[1]
Tradename:Neoral, Sandimmune, Restasis, Gengraf, other
Dailymedid:Cyclosporine
Pregnancy Au:C
Routes Of Administration:Oral, intravenous (IV), eye drops
Class:Calcineurin inhibitor
Atc Prefix:L04
Atc Suffix:AD01
Legal Au:S4
Legal Ca:Rx-only
Legal Ca Comment:[2] [3] [4]
Legal Uk:POM
Legal Us:Rx-only
Legal Us Comment:[5]
Legal Eu:Rx-only
Legal Eu Comment:[6]
Legal Status:Rx-only
Bioavailability:variable
Metabolism:Liver CYP3A4
Elimination Half-Life:variable (about 24 hours)
Excretion:Bile duct
Cas Number:59865-13-3
Pubchem:5284373
Iuphar Ligand:1024
Drugbank:DB00091
Chemspiderid:4447449
Unii:83HN0GTJ6D
Kegg:D00184
Chebi:4031
Chembl:160
Pdb Ligand:PRD_000142
Synonyms:cyclosporin, ciclosporin A,[7] cyclosporine A, cyclosporin A (CsA)
Iupac Name:(3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-Ethyl-33-[(1''R'',2''R'',4''E'')-1-hydroxy-2-methyl-4-hexen-1-yl]-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
C:62
H:111
N:11
O:12
Smiles:CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C
Stdinchi:1S/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t40-,41+,42-,43+,44+,45+,46+,47+,49+,50+,51+,52-/m1/s1
Stdinchikey:PMATZTZNYRCHOR-CGLBZJNRSA-N

Ciclosporin, also spelled cyclosporine and cyclosporin, is a calcineurin inhibitor, used as an immunosuppressant medication. It is taken orally or intravenously for rheumatoid arthritis, psoriasis, Crohn's disease, nephrotic syndrome, eczema, and in organ transplants to prevent rejection.[8] [9] It is also used as eye drops for keratoconjunctivitis sicca (dry eyes).[10]

Common side effects include high blood pressure, headache, kidney problems, increased hair growth, and vomiting.[9] Other severe side effects include an increased risk of infection, liver problems, and an increased risk of lymphoma.[9] Blood levels of the medication should be checked to decrease the risk of side effects.[9] Use during pregnancy may result in preterm birth; however, ciclosporin does not appear to cause birth defects.[11]

Ciclosporin is believed to work by decreasing the function of lymphocytes.[9] It does this by forming a complex with cyclophilin to block the phosphatase activity of calcineurin, which in turn decreases the production of inflammatory cytokines by T-lymphocytes.

Ciclosporin was isolated in 1971 from the fungus Tolypocladium inflatum and came into medical use in 1983.[12] It is on the World Health Organization's List of Essential Medicines.[13] [14] In 2021, it was the 175th most commonly prescribed medication in the United States, with more than 2million prescriptions.[15] [16] It is available as a generic medication.[17]

Medical uses

Ciclosporin is indicated to treat and prevent graft-versus-host disease in bone marrow transplantation and to prevent rejection of kidney, heart, and liver transplants.[18] [19] It is also approved in the US for treating of rheumatoid arthritis and psoriasis, persistent nummular keratitis following adenoviral keratoconjunctivitis,[20] and as eye drops for treating dry eyes caused by Sjögren's syndrome and meibomian gland dysfunction.[21]

In addition to these indications, ciclosporin is also used in severe atopic dermatitis,[22] It has been used in severe rheumatoid arthritis and related diseases.[23]

Ciclosporin has also been used in people with acute severe ulcerative colitis and hives that do not respond to treatment with steroids.[24]

Side effects

Side effects of ciclosporin can include gum enlargement, increased hair growth, convulsions, peptic ulcers, pancreatitis, fever, vomiting, diarrhea, confusion, increased cholesterol, trouble breathing, numbness and tingling (particularly of the lips), itchiness, high blood pressure, potassium retention (possibly leading to hyperkalemia), kidney and liver dysfunction,[25] burning sensations at finger tips, and an increased vulnerability to opportunistic fungal and viral infections. Ciclosporin causes hypertension by inducing vasoconstriction in the kidneys and increasing sodium reabsorption. The increase in blood pressure can cause cardiovascular events; it is thus recommended that the lowest effective dose for people requiring long-term treatment be used.[26]

Ciclosporin use after a kidney transplantation is associated with increased levels of uric acid in the blood and, in some cases, gout.[27]

Ciclosporin is listed as an IARC Group 1 carcinogen (i.e. there is sufficient evidence of carcinogenicity in humans),[28] specifically leading to squamous cell skin cancer and non-Hodgkin lymphoma.[29]

Pharmacology

Mechanism of action

Ciclosporin's main effect is to lower the activity of T-cells; it does so by inhibiting calcineurin in the calcineurin–phosphatase pathway and preventing the mitochondrial permeability transition pore from opening. Ciclosporin binds to the cytosolic protein cyclophilin (immunophilin) of lymphocytes, especially of T cells. This cyclosporin—cyclophilin complex inhibits calcineurin, which is normally responsible for activating the transcription of interleukin 2. In T-cells, activation of the T-cell receptor normally increases intracellular calcium, which acts via calmodulin to activate calcineurin. Calcineurin then dephosphorylates the transcription factor NF-AT (nuclear factor of activated T-cells), which moves to the T-cell nucleus and increases the transcription of genes for IL-2 and related cytokines.[30] Ciclosporin, by preventing the dephosphorylation of NF-AT, leads to reduced effector T-cell function;[31] [32] [33] it does not affect cytostatic activity.

Ciclosporin also binds to the cyclophilin D protein that constitutes part of the mitochondrial permeability transition pore (MPTP),[34] [35] thus preventing MPTP opening. The MPTP is found in the mitochondrial membrane of cardiac muscle cells. MPTP opening signifies a sudden change in the inner mitochondrial membrane permeability, allowing protons and other ions and solutes of a size up to ~1.5 kDa to go through the inner membrane. This change of permeability is considered a cellular catastrophe,[36] [37] leading to cell death. However, brief mitochondrial permeability transition pore openings play an essential physiological role in maintaining healthy mitochondrial homeostasis.[38]

Ciclosporin can induce a remission of proteinuria caused by such diseases as MCD and FSGS.[39] Ciclosporin blocks the calcineurin-mediated dephosphorylation of synaptopodin, a regulator of Rho GTPases in podocytes, thereby preserving the phosphorylation-dependent synaptopodin-14-3-3 beta interaction. Preservation of this interaction, in turn, protects synaptopodin from cathepsin L-mediated degradation. Altogether, the antiproteinuric effect of Ciclosporin results, at least in part, from the maintenance of synaptopodin protein abundance in podocytes, which, in turn, is sufficient to maintain the integrity of the glomerular filtration barrier and to safeguard against proteinuria.[40]

Pharmacokinetics

Ciclosporin is a cyclic peptide of 11 amino acids; it contains a single D-amino acid, which is rarely encountered in nature. Unlike most peptides, ciclosporin is not synthesized by ribosomes.[41]

Ciclosporin is highly metabolized in humans and animals after ingestion. The metabolites, which include cyclosporin B, C, D, E, H, and L,[42] have less than 10% of ciclosporin's immunosuppressant activity and are associated with higher kidney toxicity.[43]

Biosynthesis

Cyclosporin is synthesized by a nonribosomal peptide synthetase, cyclosporin synthetase.[44] The enzyme contains an adenylation domain, a thiolation domain, a condensation domain, and an N-methyltransferase domain. The adenylation domain is responsible for substrate recognition and activation, whereas the thiolation domain covalently binds the adenylated amino acids to phosphopantetheine, and the condensation domain elongates the peptide chain. Cyclosporin synthetase substrates include L-valine, L-leucine, L-alanine, glycine, 2-aminobutyric acid, 4-methylthreonine, and D-alanine, which is the starting amino acid in the biosynthetic process.[45] With the adenylation domain, cyclosporin synthetase generates the acyl-adenylated amino acids, then covalently binds the amino acid to phosphopantetheine through a thioester linkage. Some of the amino acid substrates become N-methylated by S-adenosyl methionine. The cyclization step releases cyclosporin from the enzyme.[46] Amino acids such as D-Ala and butenyl-methyl-L-threonine (Bmt) indicate cyclosporin synthetase requires the action of other enzymes. The racemization of L-Ala to D-Ala by alanine racemase is pyridoxal phosphate-dependent. The formation of butenyl-methyl-L-threonine is performed by a Bmt polyketide synthase that uses acetate/malonate as its starting material.[47]

Gene cluster

Tolypocladium inflatum, the species currently used for mass production of Cyclosporin, has the biosynthetic genes arranged into a 12-gene cluster. Of these 12 genes, SimA is the cyclosporin synthetase, SimB is the alanine racemase, and SimG (similar to) is the polyketide synthase.[48] These genes are associated with an active retrotransposon.[49] Although these sequences are poorly-annotated on GenBank and other databases, 90% similar sequences can be found for the Cyclosporin-producing Beauveria felina (or Amphichorda ~).[50] SimB has two paralogs in the same organism with different but overlapping functions thanks to their low specificity.[51]

History

In 1970, new strains of fungi were isolated from soil samples taken from Norway and from Wisconsin in the US by employees of Sandoz (now Novartis) in Basel, Switzerland. Both strains produced a family of natural products called cyclosporins. Two related components that had antifungal activity were isolated from extracts from these fungi. The Norwegian strain, Tolypocladium inflatum Gams, was later used for the large scale fermentation of ciclosporin.

The immunosuppressive effect of the natural product ciclosporin was discovered on 31 January 1972[52] in a screening test on immune suppression designed and implemented by Hartmann F. Stähelin at Sandoz.[53] [54] The chemical structure of cyclosporin was determined in 1976, also at Sandoz.[55] [56] The success of the drug candidate ciclosporin in preventing organ rejection was shown in kidney transplants by R.Y. Calne and colleagues at the University of Cambridge,[57] and in liver transplants performed by Thomas Starzl at the Children's Hospital of Pittsburgh. The first patient, on 9 March 1980, was a 28-year-old woman.[58] In the United States, the Food and Drug Administration (FDA) approved ciclosporin for clinical use in 1983.[59] [60] [61] [62]

Thomas Starzl's 1992 memoir explains through the eyes of a transplant surgeon that ciclosporin was an epoch-making drug for solid organ allotransplantation.[63] It greatly expanded the clinical applicability of such transplantation by substantially advancing the antirejection pharmacotherapy component.[63] Put simply, the biggest limits of applying such transplantation more widely were not cost or surgical skill (as formidable as those are) but rather the problem of allograft rejection and the scarcity of donor organs. Ciclopsporin was a major advancement against the rejection part of the challenge.[63]

Society and culture

Legal status

In July 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Vevizye, intended for the treatment of dry eye disease. The applicant for this medicinal product is Novaliq GmbH.[64]

Names

The natural product was named cyclosporin by the German-speaking scientists who first isolated it and cyclosporine when translated into English. Per International Nonproprietary Name (INN) guidelines for drugs,[65] the y was replaced with i so that the INN for the medication is spelled ciclosporin.

Ciclosporin is the INN and the British Approved Name (BAN), while cyclosporine is the United States Adopted Name (USAN) and cyclosporin is a former BAN.[66]

Available forms

Ciclosporin exhibits very poor solubility in water, and, as a consequence, suspension and emulsion forms of the medication have been developed for oral administration and for injection. Ciclosporin was originally brought to market by Sandoz (now Novartis), under the brand name Sandimmune, which is available as soft gelatin capsules, an oral solution, and a formulation for intravenous administration. These are all nonaqueous compositions. A newer microemulsion,[67] orally-administered formulation, Neoral, is available as a solution and as soft gelatin capsules. Compositions of Neoral are designed to form microemulsions in contact with water.[68] [69]

Generic ciclosporin preparations have been marketed under various brand names, including Cicloral (by Sandoz/Hexal), Gengraf (by Abbott) and Deximune (by Dexcel Pharma). Since 2002, a topical emulsion of ciclosporin for treating inflammation caused by keratoconjunctivitis sicca (dry eye syndrome) has been marketed under the brand name Restasis. Ikervis is a similar formulation with a concentration of 0.1%.[70] Inhaled ciclosporin formulations are in clinical development, and include a solution in propylene glycol and liposome dispersions.[71] [72]

Research

Neuroprotection

Ciclosporin is in a phase II/III (adaptive) clinical study in Europe to determine its ability to ameliorate neuronal cellular damage and reperfusion injury (phase III) in traumatic brain injury. This multi-center study is being organized by NeuroVive Pharma and the European Brain Injury Consortium using NeuroVive's formulation of ciclosporin called Neurostat (also known by its cardioprotection brand name of Ciclomulsion). This formulation uses a lipid emulsion base instead of cremophor and ethanol.[73] NeuroSTAT was compared to Sandimmune in a phase I study and found to be bioequivalent. In this study, NeuroSTAT did not exhibit the anaphylactic and hypersensitivity reactions found in cremophor- and ethanol-based products.[74]

Ciclosporin has been investigated as a possible neuroprotective agent in conditions such as traumatic brain injury, and has been shown in animal experiments to reduce brain damage associated with injury.[75] Ciclosporin blocks the formation of the mitochondrial permeability transition pore, which has been found to cause much of the damage associated with head injury and neurodegenerative diseases. Ciclosporin's neuroprotective properties were first discovered in the early 1990s when two researchers (Eskil Elmér and Hiroyuki Uchino) were conducting experiments in cell transplantation. An unintended finding was that cyclosporin A was strongly neuroprotective when it crossed the blood–brain barrier.[76] This same process of mitochondrial destruction through the opening of the MPT pore is implicated in making traumatic brain injuries much worse.[77]

Cardiac disease

Ciclosporin has been used experimentally to treat cardiac hypertrophy[34] [78] (an increase in cell volume).

Inappropriate opening of the mitochondrial permeability transition pore (MPTP) manifests in ischemia[34] (blood flow restriction to tissue) and reperfusion injury[34] (damage occurring after ischemia when blood flow returns to tissue), after myocardial infarction[32] (heart attack) and when mutations in mitochondrial DNA polymerase occur.[34] The heart attempts to compensate for disease state by increasing the intracellular to increase the contractility cycling rates.[35] Constitutively high levels of mitochondrial cause inappropriate MPTP opening leading to a decrease in the cardiac range of function, leading to cardiac hypertrophy as an attempt to compensate for the problem.[35] [32]

Cyclosporin A has been shown to decrease cardiac hypertrophy by affecting cardiac myocytes in many ways. Cyclosporin A binds to cyclophilin D to block the opening of MPTP, and thus decreases the release of protein cytochrome C, which can cause programmed cell death.[34] [35] [79] CypD is a protein within the MPTP that acts as a gate; binding by cyclosporin A decreases the amount of inappropriate opening of MPTP, which decreases the intramitochondrial .[35] Decreasing intramitochondrial allows for reversal of cardiac hypertrophy caused in the original cardiac response.[35] Decreasing the release of cytochrome C caused decreased cell death during injury and disease.[34] Cyclosporin A also inhibits the phosphatase calcineurin pathway (14).[34] [32] [80] Inhibition of this pathway has been shown to decrease myocardial hypertrophy.[32] [78] [80]

Veterinary use

The medication is approved in the United States for the treatment of atopic dermatitis in dogs.[81] Unlike the human form of the medication, the lower doses used in dogs mean the drug acts as an immunomodulator and has fewer side effects than in humans. The benefits of using this product include the reduced need for concurrent therapies to bring the condition under control. It is available as an ophthalmic ointment for dogs called Optimmune, manufactured by Intervet, which is part of Merck. It is also used to treat sebaceous adenitis (immune response against the sebaceous glands), pemphigus foliaceus (autoimmune blistering skin disease), Inflammatory bowel disease, anal furunculosis (anal inflammatory disease), and myasthenia gravis (a neuromuscular disease).[81] [82]

Notes and References

  1. Web site: cyclosporin. Dictionary.com Unabridged. Random House. n.d.. 13 July 2011. live. https://web.archive.org/web/20101118062350/http://dictionary.reference.com/browse/cyclosporin. 18 November 2010.
  2. Web site: Regulatory Decision Summary for Restasis Multidose . Drug and Health Product Register . 23 October 2014 . 7 June 2022 . 7 June 2022 . https://web.archive.org/web/20220607082031/https://hpr-rps.hres.ca/reg-content/regulatory-decision-summary-detail.php?lang=en&linkID=RDS00456 . live .
  3. Web site: Regulatory Decision Summary for Verkazia . Drug and Health Product Register . 23 October 2014 . 7 June 2022 . 7 June 2022 . https://web.archive.org/web/20220607082151/https://hpr-rps.hres.ca/reg-content/regulatory-decision-summary-detail.php?lang=en&linkID=RDS00501 . live .
  4. Web site: Health product highlights 2021: Annexes of products approved in 2021 . . 3 August 2022 . 25 March 2024.
  5. Web site: Vevye- cyclosporine ophthalmic solution solution/ drops . DailyMed . 26 May 2023 . 29 August 2023 . 29 August 2023 . https://web.archive.org/web/20230829052022/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5b74d85-86ae-41aa-8733-077f6d2779dd . live .
  6. Web site: Ikervis . European Medicines Agency . 17 September 2018 . 27 February 2023 . 13 August 2022 . https://web.archive.org/web/20220813012529/https://www.ema.europa.eu/en/medicines/human/EPAR/ikervis . live .
  7. Laupacis A, Keown PA, Ulan RA, McKenzie N, Stiller CR . Cyclosporin A: a powerful immunosuppressant . Canadian Medical Association Journal . 126 . 9 . 1041–6 . May 1982 . 7074504 . 1863293 .
  8. Book: WHO Model Formulary 2008 . 2009 . 9789241547659 . ((World Health Organization)) . Stuart MC, Kouimtzi M, Hill SR . 10665/44053 . World Health Organization . World Health Organization . free . 221 .
  9. Web site: Cyclosporine. The American Society of Health-System Pharmacists. 8 December 2016. live. https://web.archive.org/web/20161017140204/https://www.drugs.com/monograph/cyclosporine.html. 17 October 2016.
  10. Web site: Cyclosporine eent . The American Society of Health-System Pharmacists . 8 December 2016 . live . https://web.archive.org/web/20160113234854/http://www.drugs.com/monograph/cyclosporine-eent.html . 13 January 2016 .
  11. Web site: Cyclosporine Use During Pregnancy. Drugs.com. https://web.archive.org/web/20170914034946/https://www.drugs.com/pregnancy/cyclosporine.html. 14 September 2017. live. 20 December 2016.
  12. Book: Watts R, Clunie G, Hall F, Marshall T . Rheumatology . 2009 . Oxford University Press . 978-0-19-922999-4 . 558 . live . https://web.archive.org/web/20171105200103/https://books.google.com/books?id=1m_59s7Tt3UC&pg=PA558 . 5 November 2017 .
  13. Book: ((World Health Organization)) . World Health Organization model list of essential medicines: 21st list 2019 . 2019 . 10665/325771 . World Health Organization . World Health Organization . Geneva . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO . free .
  14. Book: ((World Health Organization)) . World Health Organization model list of essential medicines: 22nd list (2021) . 2021 . 10665/345533 . World Health Organization . World Health Organization . Geneva . WHO/MHP/HPS/EML/2021.02 . free .
  15. Web site: The Top 300 of 2021 . ClinCalc . 14 January 2024 . 15 January 2024 . https://web.archive.org/web/20240115223848/https://clincalc.com/DrugStats/Top300Drugs.aspx . live .
  16. Web site: Cyclosporine - Drug Usage Statistics . ClinCalc . 14 January 2024.
  17. FDA Approves First Generic of Restasis . U.S. Food and Drug Administration (FDA) . 2 February 2022 . 3 February 2022 . 2 February 2022 . https://web.archive.org/web/20220202222334/https://www.fda.gov/news-events/press-announcements/fda-approves-first-generic-restasis . live .
  18. Web site: Sandimmune- cyclosporine capsule, liquid filled Sandimmune- cyclosporine injection Sandimmune- cyclosporine solution . DailyMed . 3 February 2022 . 21 April 2014 . https://web.archive.org/web/20140421050517/http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5e5926a7-1de0-4b54-a5c0-286b6200ff82 . live .
  19. Web site: Neoral- cyclosporine capsule, liquid filled Neoral- cyclosporine solution . DailyMed . 3 February 2022 . 5 July 2013 . https://web.archive.org/web/20130705213921/http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=94461af3-11f1-4670-95d4-2965b9538ae3 . live .
  20. Lokales Cyclosporin A bei Nummuli nach Keratoconjunctivitis epidemica Eine Pilotstudie - Springer . 10.1007/s003470070025 . 11130165 . 97. 11 . Der Ophthalmologe. 764–768. Reinhard T. 2000 . 399211 .
  21. Web site: Restasis- cyclosporine emulsion . DailyMed . 3 February 2022 . 30 March 2014 . https://web.archive.org/web/20140330102448/http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8e24af2b-bc1c-4849-94f2-6df950cdca89 . live .
  22. Paolino A, Alexander H, Broderick C, Flohr C . May 2023 . Non-biologic systemic treatments for atopic dermatitis: Current state of the art and future directions . Clinical and Experimental Allergy . 53 . 5 . 495–510 . 10.1111/cea.14301 . 36949024 . free.
  23. Dijkmans BA, van Rijthoven AW, Goei Thè HS, Boers M, Cats A . Cyclosporine in rheumatoid arthritis . Seminars in Arthritis and Rheumatism . 22 . 1 . 30–36 . August 1992 . 1411580 . 10.1016/0049-0172(92)90046-g .
  24. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, Michelassi F, Hanauer S. June 1994. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. The New England Journal of Medicine. 330. 26. 1841–5. 10.1056/NEJM199406303302601. 8196726. free.
  25. Naesens M, Kuypers DR, Sarwal M . Calcineurin inhibitor nephrotoxicity . Clinical Journal of the American Society of Nephrology . 4 . 2 . 481–508 . February 2009 . 19218475 . 10.2215/CJN.04800908 . free . doi . 20 April 2018 . 20 July 2018 . https://web.archive.org/web/20180720232856/http://cjasn.asnjournals.org/content/4/2/481.full.pdf . live .
  26. Robert N, Wong GW, Wright JM . Effect of cyclosporine on blood pressure . Cochrane Database of Systematic Reviews . 1 . CD007893 . January 2010 . 20091657 . 10.1002/14651858.CD007893.pub2 .
  27. Figg WD . Cyclosporine-induced hyperuricemia and gout . The New England Journal of Medicine . 322 . 5 . 334–336 . February 1990 . 2296276 . 10.1056/NEJM199002013220514 . free .
  28. http://monographs.iarc.fr/ENG/Classification/ClassificationsGroupOrder.pdf Agents Classified by the IARC Monographs, Volumes 1–110
  29. Book: IARC Working Group on the Evaluation of Carcinogenic Risk to Humans. Ciclosporin. 2012. International Agency for Research on Cancer. 23 February 2018. 28 August 2021. https://web.archive.org/web/20210828035817/https://www.ncbi.nlm.nih.gov/books/NBK304321/. live.
  30. Matsuda S, Koyasu S. May 2000. Mechanisms of action of cyclosporine. Immunopharmacology. 47. 2–3. 119–25. 10.1016/S0162-3109(00)00192-2. 10878286. 4 March 2018. https://web.archive.org/web/20170811222815/http://web.khu.ac.kr/%7Ebiochem/source1.pdf. 11 August 2017. dead.
  31. Book: Ganong WF . Review of medical physiology . limited . 2005 . McGraw-Hill Medical . New York . 978-0-07-144040-0 . 22nd . 27 . 530 .
  32. Youn TJ, Piao H, Kwon JS, Choi SY, Kim HS, Park DG, Kim DW, Kim YG, Cho MC . Effects of the calcineurin dependent signaling pathway inhibition by cyclosporin A on early and late cardiac remodeling following myocardial infarction . European Journal of Heart Failure . 4 . 6 . 713–8 . December 2002 . 12453541 . 10.1016/S1388-9842(02)00120-4 . 9181082 . free . doi .
  33. Handschumacher RE, Harding MW, Rice J, Drugge RJ, Speicher DW . Cyclophilin: a specific cytosolic binding protein for cyclosporin A . Science . 226 . 4674 . 544–7 . November 1984 . 6238408 . 10.1126/science.6238408 . 1984Sci...226..544H .
  34. Mott JL, Zhang D, Freeman JC, Mikolajczak P, Chang SW, Zassenhaus HP . Cardiac disease due to random mitochondrial DNA mutations is prevented by cyclosporin A . Biochemical and Biophysical Research Communications . 319 . 4 . 1210–5 . July 2004 . 15194495 . 10.1016/j.bbrc.2004.05.104 .
  35. Elrod JW, Wong R, Mishra S, Vagnozzi RJ, Sakthievel B, Goonasekera SA, Karch J, Gabel S, Farber J, Force T, Brown JH, Murphy E, Molkentin JD . Cyclophilin D controls mitochondrial pore-dependent Ca(2+) exchange, metabolic flexibility, and propensity for heart failure in mice . Journal of Clinical Investigation . 120 . 10 . 3680–7 . October 2010 . 20890047 . 2947235 . 10.1172/JCI43171 .
  36. Briston T, Selwood DL, Szabadkai G, Duchen MR . Mitochondrial Permeability Transition: A Molecular Lesion with Multiple Drug Targets . Trends in Pharmacological Sciences . 40 . 1 . 50–70 . January 2019 . 30527591 . 10.1016/j.tips.2018.11.004 . 54470812 . 2 August 2021 . 21 January 2022 . https://web.archive.org/web/20220121060405/https://discovery.ucl.ac.uk/id/eprint/10065055/1/TiPS%20manuscript%20accepted.pdf . live .
  37. Morciano G, Giorgi C, Bonora M, Punzetti S, Pavasini R, Wieckowski MR, Campo G, Pinton P . Molecular identity of the mitochondrial permeability transition pore and its role in ischemia-reperfusion injury . Journal of Molecular and Cellular Cardiology . 78 . 142–53 . January 2015 . 25172387 . 10.1016/j.yjmcc.2014.08.015 . 11392/2149014 . free .
  38. Zorov DB, Juhaszova M, Sollott SJ . Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release . Physiological Reviews . 94 . 3 . 909–50 . July 2014 . 24987008 . 4101632 . 10.1152/physrev.00026.2013 .
  39. Treatment of focal segmental glomerulosclerosis . 16086641 . 2005 . Expert Opinion on Pharmacotherapy . 6 . 9 . 1539–1549 . 10.1517/14656566.6.9.1539 . 35867347 . Meyrier A .
  40. 18724379 . 2008 . The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A . Nature Medicine . 14 . 9 . 931–938 . 10.1038/nm.1857 . 4109287 . Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, Delfgaauw J, Chang JM, Choi HY, Campbell KN, Kim K, Reiser J, Mundel P .
  41. Borel JF . History of the discovery of cyclosporin and of its early pharmacological development . Wiener Klinische Wochenschrift . 114 . 12 . 433–7 . June 2002 . 12422576 .
    Some sources list the fungus under an alternative species name Hypocladium inflatum gams such as Pritchard and Sneader in 2005:
    * Pritchard DI . Sourcing a chemical succession for cyclosporin from parasites and human pathogens . Drug Discovery Today . 10 . 10 . 688–91 . May 2005 . 15896681 . 10.1016/S1359-6446(05)03395-7 .
    * Book: Sneader W . Drug Discovery — A History . limited . Ciclosporin . John Wiley & Sons . 298–299 . 978-0-471-89979-2 . 23 June 2005 .
    However, the name, "Beauveria nivea", also appears in several other articles including in a 2001 online publication by Harriet Upton entitled "Origin of drugs in current use: the cyclosporin story " (retrieved 19 June 2005). Mark Plotkin states in his book Medicine Quest, Penguin Books 2001, pages 46-47, that in 1996 mycology researcher Kathie Hodge found that it is in fact a species of Cordyceps.
  42. Wang CP, Hartman NR, Venkataramanan R, Jardine I, Lin FT, Knapp JE, Starzl TE, Burckart GJ . Isolation of 10 cyclosporine metabolites from human bile . Drug Metabolism and Disposition . 17 . 3 . 292–6 . 1989 . 2568911 . 3154783 .
  43. Copeland KR, Yatscoff RW, McKenna RM . Immunosuppressive activity of cyclosporine metabolites compared and characterized by mass spectroscopy and nuclear magnetic resonance . Clinical Chemistry . 36 . 2 . 225–9 . February 1990 . 2137384 . 10.1093/clinchem/36.2.225. free .
  44. Lawen A . Biosynthesis of cyclosporins and other natural peptidyl prolyl cis/trans isomerase inhibitors . Biochimica et Biophysica Acta (BBA) - General Subjects . 1850 . 10 . 2111–20 . October 2015 . 25497210 . 10.1016/j.bbagen.2014.12.009 .
  45. Dittmann J, Wenger RM, Kleinkauf H, Lawen A . Mechanism of cyclosporin A biosynthesis. Evidence for synthesis via a single linear undecapeptide precursor . Journal of Biological Chemistry . 269 . 4 . 2841–6 . January 1994 . 10.1016/S0021-9258(17)42019-9 . 8300618 . free . doi .
  46. Hoppert M, Gentzsch C, Schörgendorfer K . Structure and localization of cyclosporin synthetase, the key enzyme of cyclosporin biosynthesis in Tolypocladium inflatum . Archives of Microbiology . 176 . 4 . 285–93 . October 2001 . 11685373 . 10.1007/s002030100324 . 2001ArMic.176..285H . 33075098 .
  47. Dewick, P. (2001) Medicinal Natural Products. John Wiley & Sons, Ltd. 2nd ed.
  48. Yang X, Feng P, Yin Y, Bushley K, Spatafora JW, Wang C . Tolypocladium inflatum Benefits Fungal Adaptation to the Environment . mBio . 9 . 5 . October 2018 . 30279281 . 6168864 . 10.1128/mBio.01211-18 .
  49. Bushley KE, Raja R, Jaiswal P, Cumbie JS, Nonogaki M, Boyd AE, Owensby CA, Knaus BJ, Elser J, Miller D, Di Y, McPhail KL, Spatafora JW . The genome of tolypocladium inflatum: evolution, organization, and expression of the cyclosporin biosynthetic gene cluster . PLOS Genetics . 9 . 6 . e1003496 . June 2013 . 23818858 . 3688495 . 10.1371/journal.pgen.1003496 . free .
  50. Xu L, Li Y, Biggins JB, Bowman BR, Verdine GL, Gloer JB, Alspaugh JA, Bills GF . Identification of cyclosporin C from Amphichorda felina using a Cryptococcus neoformans differential temperature sensitivity assay . Applied Microbiology and Biotechnology . 102 . 5 . 2337–2350 . March 2018 . 29396588 . 5942556 . 10.1007/s00253-018-8792-0 .
  51. di Salvo ML, Florio R, Paiardini A, Vivoli M, D'Aguanno S, Contestabile R . Alanine racemase from Tolypocladium inflatum: a key PLP-dependent enzyme in cyclosporin biosynthesis and a model of catalytic promiscuity . Archives of Biochemistry and Biophysics . 529 . 2 . 55–65 . January 2013 . 23219598 . 10.1016/j.abb.2012.11.011 .
  52. 10.1111/ctr.12072. Hartmann Stahelin (1925-2011) and the contested history of cyclosporin A . 2013 . Cheng M . Clinical Transplantation . 27 . 3 . 326–329 . 23331048 . 39502677 .
  53. Borel JF, Feurer C, Gubler HU, Stähelin H . Biological effects of cyclosporin A: a new antilymphocytic agent . Agents and Actions . 6 . 4 . 468–75 . July 1976 . 8969 . 10.1007/bf01973261. 2862779 .
  54. Book: Merluzzi VJ, Adams J . Borel JF, Kis ZL, Beveridge T . The search for anti-inflammatory drugs case histories from concept to clinic . The history of the discovery and development of Cyclosporin (Sandimmune) . https://books.google.com/books?id=YWXlBwAAQBAJ&pg=PA27 . 27–63 . 1995 . Birkhäuser . Boston . 978-1-4615-9846-6 . live . https://web.archive.org/web/20171105200103/https://books.google.com/books?id=YWXlBwAAQBAJ&lpg=PP1&pg=PA27&f=false . 5 November 2017 .
  55. Rüegger A, Kuhn M, Lichti H, Loosli HR, Huguenin R, Quiquerez C, von Wartburg A . [Cyclosporin A, a Peptide Metabolite from Trichoderma polysporum (Link ex Pers.) Rifai, with a remarkable immunosuppressive activity] . de . Helvetica Chimica Acta . 59 . 4 . 1075–92 . 1976 . 950308 . 10.1002/hlca.19760590412 . Cyclosporin A, a Peptide Metabolite from Trichoderma polysporum (Link ex Pers.) Rifai, with a remarkable immunosuppressive activity .
  56. Heusler K, Pletscher A . The controversial early history of cyclosporin . Swiss Medical Weekly . 131 . 21–22 . 299–302 . June 2001 . 10.4414/smw.2001.09702 . 11584691 . 24662504 . free .
  57. Calne RY, White DJ, Thiru S, Evans DB, McMaster P, Dunn DC, Craddock GN, Pentlow BD, Rolles K . Cyclosporin A in patients receiving renal allografts from cadaver donors . The Lancet . 2 . 8104–5 . 1323–7 . 1978 . 82836 . 10.1016/S0140-6736(78)91970-0 . 10731038 .
  58. Starzl TE, Klintmalm GB, Porter KA, Iwatsuki S, Schröter GP . Liver transplantation with use of cyclosporin a and prednisone . The New England Journal of Medicine . 305 . 5 . 266–9 . July 1981 . 7017414 . 2772056 . 10.1056/NEJM198107303050507 .
  59. Kolata G . FDA speeds approval of cyclosporin . Science . 221 . 4617 . 1273 . September 1983 . 17776314 . 10.1126/science.221.4617.1273-a . On 2 September (1983), the Food and Drug Administration approved cyclosporin, a new drug that suppresses the immune system. . 1983Sci...221.1273K .
  60. News: Gottesman J . Milestones in Cardiac Care . Los Angeles Times . 20 March 1988 . live . https://web.archive.org/web/20170226132306/http://articles.latimes.com/1988-03-20/magazine/tm-1895_1_cardiac-care . 26 February 2017 .
  61. Web site: Columbia University Medical Center, Dept. of Surgery, Cardiac Transplant Program . First Successful Pediatric Heart Transplant [9 June 1984] ]. It [cyclosporine] gained FDA approval at the end of 1983, ... . live . https://web.archive.org/web/20170301092816/http://columbiasurgery.org/news/2015/06/08/history-medicine-first-pediatric-heart-transplant . 1 March 2017 .
  62. Web site: Drugs@FDA: FDA Approved Drug Products [Click on "Approval Date(s) and History] ]. Drug Name(s): Sandimmune (Cyclosporine), Company: Novartis, Action Date: 11/14/1983, Action Type: Approval, Submission Classification: Type 1 - New Molecular Entity, Review Priority: Priority . United States Food and Drug Administration . live . https://web.archive.org/web/20170301094731/http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050573 . 1 March 2017 .
  63. Book: Starzl, Thomas E. . 1992 . The Puzzle People: Memoirs Of A Transplant Surgeon . University of Pittsburgh Press . 10.2307/j.ctt9qh63b . 978-0-8229-3714-2 .
  64. Web site: Vevizye EPAR . European Medicines Agency . 25 July 2024 . 27 July 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  65. Web site: Guidelines on the Use of International Nonproprietary Names (INNs) for Pharmaceutical Substances . World Health Organization . 1997 . To facilitate the translation and pronunciation of INN, "f" should be used instead of "ph", "t" instead of "th", "e" instead of "ae" or "oe", and "i" instead of "y"; the use of the letters "h" and "k" should be avoided. .
  66. Web site: The Cyclosporine Story. https://web.archive.org/web/20221022224038/http://www.davidmoore.org.uk/sec04_01.htm . 22 October 2022. January 2013. 24 October 2022. www.davidmoore.org.uk.
  67. Gibaud S, Attivi D. August 2012. Microemulsions for oral administration and their therapeutic applications. Expert Opinion on Drug Delivery. 9. 8. 937–51. 10.1517/17425247.2012.694865. 22663249. 28468973. 4 March 2018. 5 March 2018. https://web.archive.org/web/20180305064739/https://hal.archives-ouvertes.fr/hal-00706176/document. live.
  68. Min DI . Neoral: a microemulsion cyclosporine . Journal of Transplant Coordination . 6 . 1 . 5–8 . March 1996 . 9157923 . 10.7182/prtr.1.6.1.f04016025hh795up . 7 February 2024 .
  69. Web site: September 2009 . Neoral . live . https://web.archive.org/web/20221020080142/http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050715s027%2C050716s028lbl.pdf . 20 October 2022 . 24 October 2022 . FDA Data Dashboard . Food and Drug Administration (FDA); Novartis.
  70. Web site: Ikervis. Santen. 3 July 2018. 3 July 2018. https://web.archive.org/web/20180703163600/http://www.santen.com/en/therapeutic-areas/asia/dryeye/ikervis/. live.
  71. .
  72. Trammer B, Amann A, Haltner-Ukomadu E, Tillmanns S, Keller M, Högger P . Comparative permeability and diffusion kinetics of cyclosporine A liposomes and propylene glycol solution from human lung tissue into human blood ex vivo . European Journal of Pharmaceutics and Biopharmaceutics . 70 . 3 . 758–64 . November 2008 . 18656538 . 10.1016/j.ejpb.2008.07.001 .
  73. Web site: Hem - NeuroVive Pharmaceutical AB. Administrator. neurovive.com. live. https://web.archive.org/web/20140106215852/http://www.neurovive.com/. 6 January 2014.
  74. Ehinger KH, Hansson MJ, Sjövall F, Elmér E . Bioequivalence and tolerability assessment of a novel intravenous ciclosporin lipid emulsion compared to branded ciclosporin in Cremophor EL . Clinical Drug Investigation . 33 . 1 . 25–34 . January 2013 . 23179472 . 3586182 . 10.1007/s40261-012-0029-x . 26 October 2018 . 26 October 2018 . https://web.archive.org/web/20181026104231/http://lup.lub.lu.se/search/ws/files/2207190/3737528.pdf . live .
  75. Sullivan PG, Thompson M, Scheff SW . Continuous infusion of cyclosporin A postinjury significantly ameliorates cortical damage following traumatic brain injury . Experimental Neurology . 161 . 2 . 631–7 . February 2000 . 10686082 . 10.1006/exnr.1999.7282 . 25190221 .
  76. Uchino H, Elmér E, Uchino K, Lindvall O, Siesjö BK . Cyclosporin A dramatically ameliorates CA1 hippocampal damage following transient forebrain ischaemia in the rat . Acta Physiologica Scandinavica . 155 . 4 . 469–71 . December 1995 . 8719269 . 10.1111/j.1748-1716.1995.tb09999.x .
  77. Sullivan PG, Sebastian AH, Hall ED . Therapeutic window analysis of the neuroprotective effects of cyclosporine A after traumatic brain injury . Journal of Neurotrauma . 28 . 2 . 311–8 . February 2011 . 21142667 . 3037811 . 10.1089/neu.2010.1646 .
  78. Mende U, Kagen A, Cohen A, Aramburu J, Schoen FJ, Neer EJ . Transient cardiac expression of constitutively active Galphaq leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways . Proceedings of the National Academy of Sciences of the United States of America . 95 . 23 . 13893–8 . November 1998 . 9811897 . 24952 . 10.1073/pnas.95.23.13893 . 1998PNAS...9513893M . free . doi .
  79. Wilkinson ST, Johnson DB, Tardif HL, Tome ME, Briehl MM . Increased cytochrome c correlates with poor survival in aggressive lymphoma . Oncology Letters . 1 . 2 . 227–230 . March 2010 . 20798784 . 2927837 . 10.3892/ol_00000040 .
  80. Lim HW, De Windt LJ, Mante J, Kimball TR, Witt SA, Sussman MA, Molkentin JD . Reversal of cardiac hypertrophy in transgenic disease models by calcineurin inhibition . Journal of Molecular and Cellular Cardiology . 32 . 4 . 697–709 . April 2000 . 10756124 . 10.1006/jmcc.2000.1113 . 10904494 .
  81. Archer TM, Boothe DM, Langston VC, Fellman CL, Lunsford KV, Mackin AJ . Oral cyclosporine treatment in dogs: a review of the literature . Journal of Veterinary Internal Medicine . 28 . 1 . 1–20 . 2014 . 24341787 . 4895546 . 10.1111/jvim.12265 .
  82. Palmeiro BS . Cyclosporine in veterinary dermatology . Veterinary Clinics of North America: Small Animal Practice . 43 . 1 . 153–71 . January 2013 . 23182330 . 10.1016/j.cvsm.2012.09.007 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Ciclosporin".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.